Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
26
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Gallagher Neil | Director | 2 | $0 | $0 | 2026-06-24 |
| Duty Stuart | Director | 2 | $0 | $0 | 2026-06-24 |
| Mendelsohn Michael | Director | 6 | $0 | $0 | 2026-06-24 |
| Biller Scott | Director | 6 | $0 | $0 | 2026-06-24 |
| Cole Douglas G. | Director | 6 | $0 | $0 | 2026-06-24 |
| Lynch Thomas J. Jr. | Director | 5 | $0 | $0 | 2026-06-24 |
| SMITH IAN F | Director | 8 | $0 | $0 | 2026-06-24 |
| GILL SIMBA | Director | 9 | $0 | $0 | 2026-06-24 |
| PARSHALL B LYNNE | Director | 5 | $0 | $0 | 2026-06-24 |
| GOTTSCHALK ADRIAN | See Remarks | 33 | $0 | $0 | 2026-04-10 |
| Maynard Ryan D | Chief Financial Officer | 1 | $0 | $0 | 2026-02-23 |
| Rivkin Anna | Chief Business Officer | 3 | $0 | $0 | 2026-01-30 |
| Costa Carlos | Chief People Officer | 20 | $0 | $591.2K | 2026-01-30 |
| LaCascia Michael | Chief Legal Officer | 6 | $0 | $0 | 2026-01-30 |
| Bellon Steven F. | Chief Scientific Officer | 12 | $0 | $190.0K | 2026-01-30 |
| Cardama Alfonso Quintas | Chief Medical Officer | 4 | $0 | $0 | 2026-01-30 |
| Flagship Ventures Opportunities Fund I General Partner LLC | Director, 10% Owner | 16 | $2.40M | $0 | 2026-01-13 |
| Humer Kristian | Chief Financial Officer | 2 | $0 | $0 | 2025-01-22 |
| Koppel Adam | Director | 4 | $0 | $0 | 2024-06-26 |
| AFEYAN NOUBAR | 10% Owner | 2 | $20.00M | $0 | 2024-05-22 |
| Cavalie Fanny | Chief Strategy/Bus Ops Officer | 3 | $0 | $72.2K | 2024-03-11 |
| Agresta Samuel | Chief Medical Officer | 6 | $0 | $2.57M | 2023-08-16 |
| Reine Allan | Chief Financial Officer | 5 | $0 | $0 | 2023-01-26 |
| KADOCH CIGALL | Director, 10% Owner | 3 | $0 | $0 | 2022-06-21 |
| DECICCO CARL | Chief Scientific Officer | 5 | $88.0K | $0 | 2021-12-09 |
| Abu Dhabi Investment Authority | Other | 3 | $2.40M | $0 | 2020-10-27 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Cole Douglas G. | Director | A Award deriv | 2026-06-24 | 2026-06-25 | 28,000 | $4.08 | $114.2K | 28,000 | SEC↗ |
| PARSHALL B LYNNE | Director | A Award deriv | 2026-06-24 | 2026-06-25 | 28,000 | $4.08 | $114.2K | 28,000 | SEC↗ |
| GILL SIMBA | Director | A Award deriv | 2026-06-24 | 2026-06-25 | 28,000 | $4.08 | $114.2K | 28,000 | SEC↗ |
| SMITH IAN F | Director | A Award deriv | 2026-06-24 | 2026-06-25 | 28,000 | $4.08 | $114.2K | 28,000 | SEC↗ |
| Mendelsohn Michael | Director | A Award deriv | 2026-06-24 | 2026-06-25 | 28,000 | $4.08 | $114.2K | 28,000 | SEC↗ |
| Gallagher Neil | Director | A Award deriv | 2026-06-24 | 2026-06-25 | 28,000 | $4.08 | $114.2K | 28,000 | SEC↗ |
| Biller Scott | Director | A Award deriv | 2026-06-24 | 2026-06-25 | 28,000 | $4.08 | $114.2K | 28,000 | SEC↗ |
| Duty Stuart | Director | A Award deriv | 2026-06-24 | 2026-06-25 | 28,000 | $4.08 | $114.2K | 28,000 | SEC↗ |
| Lynch Thomas J. Jr. | Director | A Award deriv | 2026-06-24 | 2026-06-25 | 28,000 | $4.08 | $114.2K | 28,000 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | G Gift | 2026-04-10 | 2026-04-13 | 59,208 | — | $0 | 240,792 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | G Gift | 2026-04-10 | 2026-04-13 | 59,208 | — | $0 | 270,912 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | G Gift | 2026-04-09 | 2026-04-13 | 47,497 | — | $0 | 211,704 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | G Gift | 2026-04-09 | 2026-04-13 | 47,497 | — | $0 | 0 | SEC↗ |
| Maynard Ryan D | Chief Financial Officer | A Award deriv | 2026-02-23 | 2026-02-24 | 400,000 | $5.75 | $2.30M | 400,000 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | A Award deriv | 2026-02-05 | 2026-02-06 | 1,075,000 | $5.23 | $5.62M | 1,075,000 | SEC↗ |
| Bellon Steven F. | Chief Scientific Officer | A Award deriv | 2026-01-30 | 2026-02-02 | 300,000 | $5.71 | $1.71M | 300,000 | SEC↗ |
| Rivkin Anna | Chief Business Officer | A Award deriv | 2026-01-30 | 2026-02-02 | 165,000 | $5.71 | $942.1K | 165,000 | SEC↗ |
| Cardama Alfonso Quintas | Chief Medical Officer | A Award deriv | 2026-01-30 | 2026-02-02 | 300,000 | $5.71 | $1.71M | 300,000 | SEC↗ |
| LaCascia Michael | Chief Legal Officer | A Award deriv | 2026-01-30 | 2026-02-02 | 295,000 | $5.71 | $1.68M | 295,000 | SEC↗ |
| Costa Carlos | Chief People Officer | A Award deriv | 2026-01-30 | 2026-02-02 | 230,000 | $5.71 | $1.31M | 230,000 | SEC↗ |
| Flagship Ventures Opportunitie | Director, 10% Owner | A Award deriv | 2026-01-13 | 2026-01-15 | 2,235,468 | $6.71 | $15.00M | 2,235,468 | SEC↗ |
| Flagship Ventures Opportunitie | Director, 10% Owner | A Award deriv | 2026-01-13 | 2026-01-15 | 1,117,734 | — | $0 | 1,117,734 | SEC↗ |
| Flagship Ventures Opportunitie | Director, 10% Owner | A Award deriv | 2026-01-13 | 2026-01-15 | 1,117,734 | — | $0 | 1,117,734 | SEC↗ |
| Cole Douglas G. | Director | A Award deriv | 2025-06-17 | 2025-06-17 | 25,000 | $4.79 | $119.8K | 25,000 | SEC↗ |
| Biller Scott | Director | A Award deriv | 2025-06-17 | 2025-06-17 | 25,000 | $4.79 | $119.8K | 25,000 | SEC↗ |
| GILL SIMBA | Director | A Award deriv | 2025-06-17 | 2025-06-17 | 25,000 | $4.79 | $119.8K | 25,000 | SEC↗ |
| Lynch Thomas J. Jr. | Director | A Award deriv | 2025-06-17 | 2025-06-17 | 25,000 | $4.79 | $119.8K | 25,000 | SEC↗ |
| Mendelsohn Michael | Director | A Award deriv | 2025-06-17 | 2025-06-17 | 25,000 | $4.79 | $119.8K | 25,000 | SEC↗ |
| PARSHALL B LYNNE | Director | A Award deriv | 2025-06-17 | 2025-06-17 | 25,000 | $4.79 | $119.8K | 25,000 | SEC↗ |
| SMITH IAN F | Director | A Award deriv | 2025-06-17 | 2025-06-17 | 25,000 | $4.79 | $119.8K | 25,000 | SEC↗ |
| Duty Stuart | Director | A Award deriv | 2025-05-01 | 2025-05-02 | 50,000 | $4.16 | $208.0K | 50,000 | SEC↗ |
| Gallagher Neil | Director | A Award deriv | 2025-05-01 | 2025-05-02 | 50,000 | $4.16 | $208.0K | 50,000 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | G Gift | 2025-04-25 | 2025-04-28 | 300,000 | — | $0 | 511,704 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | G Gift | 2025-04-25 | 2025-04-28 | 300,000 | — | $0 | 511,704 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | G Gift | 2025-04-09 | 2025-04-10 | 197,906 | — | $0 | 511,704 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | G Gift | 2025-04-09 | 2025-04-10 | 197,906 | — | $0 | 511,704 | SEC↗ |
| LaCascia Michael | Chief Legal Officer | A Award deriv | 2025-01-22 | 2025-01-24 | 126,000 | $4.37 | $550.6K | 126,000 | SEC↗ |
| Bellon Steven F. | Chief Scientific Officer | A Award deriv | 2025-01-22 | 2025-01-24 | 140,000 | $4.37 | $611.8K | 140,000 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | A Award deriv | 2025-01-22 | 2025-01-24 | 400,000 | $4.37 | $1.75M | 400,000 | SEC↗ |
| Rivkin Anna | Chief Business Officer | A Award deriv | 2025-01-22 | 2025-01-24 | 50,000 | $4.37 | $218.5K | 50,000 | SEC↗ |
| Costa Carlos | Chief People Officer | A Award deriv | 2025-01-22 | 2025-01-24 | 115,000 | $4.37 | $502.6K | 115,000 | SEC↗ |
| Humer Kristian | Chief Financial Officer | A Award deriv | 2025-01-22 | 2025-01-24 | 120,000 | $4.37 | $524.4K | 120,000 | SEC↗ |
| Cardama Alfonso Quintas | Chief Medical Officer | A Award deriv | 2025-01-22 | 2025-01-24 | 125,000 | $4.37 | $546.3K | 125,000 | SEC↗ |
| Costa Carlos | Chief People Officer | M Exercise deriv | 2024-09-23 | 2024-09-24 | 857 | — | $0 | 39,789 | SEC↗ |
| Costa Carlos | Chief People Officer | S Sale | 2024-09-23 | 2024-09-24 | 857 | $10.17 | $8.7K | 0 | SEC↗ |
| Costa Carlos | Chief People Officer | M Exercise | 2024-09-23 | 2024-09-24 | 857 | $3.72 | $3.2K | 857 | SEC↗ |
| Costa Carlos | Chief People Officer | M Exercise deriv | 2024-09-20 | 2024-09-24 | 35,756 | — | $0 | 40,646 | SEC↗ |
| Costa Carlos | Chief People Officer | M Exercise | 2024-09-20 | 2024-09-24 | 35,756 | $3.72 | $133.0K | 35,756 | SEC↗ |
| Costa Carlos | Chief People Officer | S Sale | 2024-09-20 | 2024-09-24 | 35,756 | $10.04 | $359.0K | 0 | SEC↗ |
| Costa Carlos | Chief People Officer | M Exercise deriv | 2024-09-18 | 2024-09-20 | 11,574 | — | $0 | 76,402 | SEC↗ |
| Costa Carlos | Chief People Officer | S Sale | 2024-09-18 | 2024-09-20 | 11,574 | $10.05 | $116.3K | 0 | SEC↗ |
| Costa Carlos | Chief People Officer | M Exercise | 2024-09-18 | 2024-09-20 | 11,574 | $3.72 | $43.1K | 11,574 | SEC↗ |
| Costa Carlos | Chief People Officer | M Exercise deriv | 2024-09-17 | 2024-09-18 | 10,272 | — | $0 | 87,976 | SEC↗ |
| Costa Carlos | Chief People Officer | S Sale | 2024-09-17 | 2024-09-18 | 10,272 | $10.04 | $103.1K | 0 | SEC↗ |
| Costa Carlos | Chief People Officer | M Exercise | 2024-09-17 | 2024-09-18 | 10,272 | $3.72 | $38.2K | 10,272 | SEC↗ |
| Costa Carlos | Chief People Officer | M Exercise deriv | 2024-09-16 | 2024-09-18 | 400 | — | $0 | 98,248 | SEC↗ |
| Costa Carlos | Chief People Officer | S Sale | 2024-09-16 | 2024-09-18 | 400 | $10.00 | $4.0K | 0 | SEC↗ |
| Costa Carlos | Chief People Officer | M Exercise | 2024-09-16 | 2024-09-18 | 400 | $3.72 | $1.5K | 400 | SEC↗ |
| Bellon Steven F. | Chief Scientific Officer | S Sale | 2024-09-09 | 2024-09-11 | 20,000 | $9.50 | $190.0K | 101,957 | SEC↗ |
| Rivkin Anna | Chief Business Officer | A Award deriv | 2024-09-03 | 2024-09-04 | 190,000 | $7.85 | $1.49M | 190,000 | SEC↗ |
| Koppel Adam | Director | A Award deriv | 2024-06-26 | 2024-06-28 | 16,000 | $5.52 | $88.3K | 16,000 | SEC↗ |
| PARSHALL B LYNNE | Director | A Award deriv | 2024-06-26 | 2024-06-28 | 16,000 | $5.52 | $88.3K | 16,000 | SEC↗ |
| Cole Douglas G. | Director | A Award deriv | 2024-06-26 | 2024-06-28 | 16,000 | $5.52 | $88.3K | 16,000 | SEC↗ |
| GILL SIMBA | Director | A Award deriv | 2024-06-26 | 2024-06-28 | 16,000 | $5.52 | $88.3K | 16,000 | SEC↗ |
| Lynch Thomas J. Jr. | Director | A Award deriv | 2024-06-26 | 2024-06-28 | 16,000 | $5.52 | $88.3K | 16,000 | SEC↗ |
| SMITH IAN F | Director | A Award deriv | 2024-06-26 | 2024-06-28 | 16,000 | $5.52 | $88.3K | 16,000 | SEC↗ |
| Mendelsohn Michael | Director | A Award deriv | 2024-06-26 | 2024-06-28 | 16,000 | $5.52 | $88.3K | 16,000 | SEC↗ |
| Biller Scott | Director | A Award deriv | 2024-06-26 | 2024-06-28 | 16,000 | $5.52 | $88.3K | 16,000 | SEC↗ |
| AFEYAN NOUBAR | 10% Owner | P Buy deriv | 2024-05-22 | 2024-05-24 | 1,814,915 | $5.51 | $10.00M | 1,814,915 | SEC↗ |
| AFEYAN NOUBAR | 10% Owner | P Buy deriv | 2024-05-22 | 2024-05-24 | 1,814,914 | $5.51 | $10.00M | 1,814,914 | SEC↗ |
| Humer Kristian | Chief Financial Officer | A Award deriv | 2024-04-16 | 2024-04-17 | 275,000 | $6.03 | $1.66M | 275,000 | SEC↗ |
| Cavalie Fanny | Chief Strategy/Bus Ops Offic | S Sale | 2024-03-11 | 2024-03-12 | 11,000 | $6.56 | $72.2K | 75,992 | SEC↗ |
| LaCascia Michael | Chief Legal Officer | A Award deriv | 2024-01-24 | 2024-01-25 | 100,000 | $3.06 | $306.0K | 100,000 | SEC↗ |
| Bellon Steven F. | Chief Scientific Officer | A Award deriv | 2024-01-24 | 2024-01-25 | 110,000 | $3.06 | $336.6K | 110,000 | SEC↗ |
| Costa Carlos | Chief People Officer | A Award deriv | 2024-01-24 | 2024-01-25 | 90,000 | $3.06 | $275.4K | 90,000 | SEC↗ |
| Cavalie Fanny | Chief Strategy/Bus Ops Offic | A Award deriv | 2024-01-24 | 2024-01-25 | 80,000 | $3.06 | $244.8K | 80,000 | SEC↗ |
| Cardama Alfonso Quintas | Chief Medical Officer | A Award deriv | 2024-01-24 | 2024-01-25 | 60,000 | $3.06 | $183.6K | 60,000 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | A Award deriv | 2024-01-24 | 2024-01-25 | 300,000 | $3.06 | $918.0K | 300,000 | SEC↗ |
| SMITH IAN F | Director | A Award deriv | 2023-12-08 | 2023-12-12 | 26,977 | — | $0 | 26,977 | SEC↗ |
| Cardama Alfonso Quintas | Chief Medical Officer | A Award deriv | 2023-09-11 | 2023-09-13 | 272,000 | $7.57 | $2.06M | 272,000 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | G Gift | 2023-08-17 | 2023-08-18 | 63,000 | — | $0 | 0 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | G Gift | 2023-08-17 | 2023-08-18 | 63,000 | — | $0 | 511,704 | SEC↗ |
| Agresta Samuel | Chief Medical Officer | M Exercise deriv | 2023-08-16 | 2023-08-18 | 311,297 | — | $0 | 0 | SEC↗ |
| Agresta Samuel | Chief Medical Officer | S Sale | 2023-08-16 | 2023-08-18 | 311,297 | $8.25 | $2.57M | 0 | SEC↗ |
| Agresta Samuel | Chief Medical Officer | M Exercise | 2023-08-16 | 2023-08-18 | 311,297 | $3.72 | $1.16M | 311,297 | SEC↗ |
| Mendelsohn Michael | Director | A Award deriv | 2023-06-21 | 2023-06-22 | 16,000 | — | $0 | 16,000 | SEC↗ |
| GILL SIMBA | Director | A Award deriv | 2023-06-21 | 2023-06-22 | 16,000 | — | $0 | 16,000 | SEC↗ |
| Koppel Adam | Director | A Award deriv | 2023-06-21 | 2023-06-22 | 16,000 | — | $0 | 16,000 | SEC↗ |
| Biller Scott | Director | A Award deriv | 2023-06-21 | 2023-06-22 | 16,000 | — | $0 | 16,000 | SEC↗ |
| SMITH IAN F | Director | A Award deriv | 2023-06-21 | 2023-06-22 | 16,000 | — | $0 | 16,000 | SEC↗ |
| Cole Douglas G. | Director | A Award deriv | 2023-06-21 | 2023-06-22 | 16,000 | — | $0 | 16,000 | SEC↗ |
| Lynch Thomas J. Jr. | Director | A Award deriv | 2023-06-21 | 2023-06-22 | 16,000 | — | $0 | 16,000 | SEC↗ |
| PARSHALL B LYNNE | Director | A Award deriv | 2023-06-21 | 2023-06-22 | 16,000 | — | $0 | 16,000 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | G Gift | 2023-05-26 | 2023-05-31 | 300,000 | — | $0 | 448,704 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | G Gift | 2023-05-26 | 2023-05-31 | 300,000 | — | $0 | 448,704 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | G Gift | 2023-02-17 | 2023-02-22 | 4,371 | — | $0 | 63,000 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | G Gift | 2023-02-17 | 2023-02-22 | 4,371 | — | $0 | 448,704 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | J Other | 2023-02-17 | 2023-02-22 | 184,939 | — | $0 | 448,704 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | J Other | 2023-02-17 | 2023-02-22 | 184,939 | — | $0 | 448,704 | SEC↗ |
| Reine Allan | Chief Financial Officer | A Award deriv | 2023-01-26 | 2023-01-30 | 90,000 | — | $0 | 90,000 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | A Award deriv | 2023-01-26 | 2023-01-30 | 280,000 | — | $0 | 280,000 | SEC↗ |
| LaCascia Michael | Chief Legal Officer | A Award deriv | 2023-01-26 | 2023-01-30 | 90,000 | — | $0 | 90,000 | SEC↗ |
| Costa Carlos | Chief People Officer | A Award deriv | 2023-01-26 | 2023-01-30 | 65,000 | — | $0 | 65,000 | SEC↗ |
| Bellon Steven F. | Chief Scientific Officer | A Award deriv | 2023-01-26 | 2023-01-30 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Cavalie Fanny | Chief Strategy/Bus Ops Offic | A Award deriv | 2023-01-26 | 2023-01-30 | 65,000 | — | $0 | 65,000 | SEC↗ |
| Agresta Samuel | Chief Medical Officer | A Award deriv | 2023-01-26 | 2023-01-30 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Lynch Thomas J. Jr. | Director | A Award deriv | 2022-10-27 | 2022-10-31 | 32,000 | $8.23 | $263.4K | 32,000 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | J Other | 2022-10-25 | 2023-02-22 | 4,371 | — | $0 | 444,333 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | J Other | 2022-10-25 | 2023-02-22 | 4,371 | — | $0 | 67,371 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | M Exercise deriv | 2022-09-16 | 2022-09-19 | 40,000 | — | $0 | 418,925 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | M Exercise | 2022-09-16 | 2022-09-19 | 40,000 | $0.54 | $21.6K | 186,479 | SEC↗ |
| GILL SIMBA | Director | G Gift | 2022-09-13 | 2022-09-14 | 47,939 | — | $0 | 34,061 | SEC↗ |
| GILL SIMBA | Director | M Exercise deriv | 2022-09-12 | 2022-09-14 | 82,000 | — | $0 | 107,188 | SEC↗ |
| GILL SIMBA | Director | M Exercise | 2022-09-12 | 2022-09-14 | 82,000 | $0.73 | $59.9K | 82,000 | SEC↗ |
| PARSHALL B LYNNE | Director | A Award deriv | 2022-08-16 | 2022-08-18 | 32,000 | $16.34 | $522.9K | 32,000 | SEC↗ |
| Bellon Steven F. | Chief Scientific Officer | M Exercise deriv | 2022-08-11 | 2022-08-15 | 1,858 | — | $0 | 3,716 | SEC↗ |
| Bellon Steven F. | Chief Scientific Officer | M Exercise | 2022-08-11 | 2022-08-15 | 1,858 | $3.72 | $6.9K | 121,957 | SEC↗ |
| Costa Carlos | Chief People Officer | A Award deriv | 2022-08-01 | 2022-08-03 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Koppel Adam | Director | A Award deriv | 2022-06-21 | 2022-06-22 | 16,000 | — | $0 | 16,000 | SEC↗ |
| GILL SIMBA | Director | A Award deriv | 2022-06-21 | 2022-06-22 | 16,000 | — | $0 | 16,000 | SEC↗ |
| KADOCH CIGALL | Director, 10% Owner | A Award deriv | 2022-06-21 | 2022-06-22 | 16,000 | — | $0 | 16,000 | SEC↗ |
| SMITH IAN F | Director | A Award deriv | 2022-06-21 | 2022-06-22 | 16,000 | — | $0 | 16,000 | SEC↗ |
| Cole Douglas G. | Director | A Award deriv | 2022-06-21 | 2022-06-22 | 16,000 | — | $0 | 16,000 | SEC↗ |
| Mendelsohn Michael | Director | A Award deriv | 2022-06-21 | 2022-06-22 | 16,000 | — | $0 | 16,000 | SEC↗ |
| Biller Scott | Director | A Award deriv | 2022-06-21 | 2022-06-22 | 16,000 | — | $0 | 16,000 | SEC↗ |
| Bellon Steven F. | Chief Scientific Officer | M Exercise deriv | 2022-05-25 | 2022-05-27 | 3,717 | — | $0 | 5,574 | SEC↗ |
| Bellon Steven F. | Chief Scientific Officer | M Exercise deriv | 2022-05-25 | 2022-05-27 | 675 | — | $0 | 0 | SEC↗ |
| Bellon Steven F. | Chief Scientific Officer | M Exercise | 2022-05-25 | 2022-05-27 | 3,717 | $3.72 | $13.8K | 120,099 | SEC↗ |
| Bellon Steven F. | Chief Scientific Officer | M Exercise | 2022-05-25 | 2022-05-27 | 675 | $0.73 | $493 | 116,382 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | G Gift | 2022-02-10 | 2023-02-22 | 123,479 | — | $0 | 448,704 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | G Gift | 2022-02-10 | 2023-02-22 | 123,479 | — | $0 | 23,000 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | A Award deriv | 2022-01-26 | 2022-01-28 | 440,000 | — | $0 | 440,000 | SEC↗ |
| Reine Allan | Chief Financial Officer | A Award deriv | 2022-01-26 | 2022-01-28 | 135,000 | — | $0 | 135,000 | SEC↗ |
| LaCascia Michael | Chief Legal Officer | A Award deriv | 2022-01-26 | 2022-01-28 | 135,000 | — | $0 | 135,000 | SEC↗ |
| Bellon Steven F. | Chief Scientific Officer | A Award deriv | 2022-01-26 | 2022-01-28 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Agresta Samuel | Chief Medical Officer | A Award deriv | 2022-01-26 | 2022-01-28 | 125,000 | — | $0 | 125,000 | SEC↗ |
| KADOCH CIGALL | Director, 10% Owner | G Gift | 2021-12-14 | 2021-12-16 | 333,333 | — | $0 | 295,000 | SEC↗ |
| DECICCO CARL | Chief Scientific Officer | M Exercise deriv | 2021-12-09 | 2021-12-13 | 76,892 | — | $0 | 186,571 | SEC↗ |
| DECICCO CARL | Chief Scientific Officer | M Exercise deriv | 2021-12-09 | 2021-12-13 | 27,418 | — | $0 | 34,273 | SEC↗ |
| DECICCO CARL | Chief Scientific Officer | M Exercise | 2021-12-09 | 2021-12-13 | 104,310 | $3.72 | $388.0K | 362,707 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | M Exercise deriv | 2021-08-20 | 2021-08-23 | 23,000 | — | $0 | 458,925 | SEC↗ |
| GOTTSCHALK ADRIAN | Chief Executive Officer | M Exercise | 2021-08-20 | 2021-08-23 | 23,000 | $0.54 | $12.4K | 446,479 | SEC↗ |
| Reine Allan | Chief Financial Officer | M Exercise deriv | 2021-08-09 | 2021-08-11 | 26,892 | — | $0 | 257,512 | SEC↗ |
| Reine Allan | Chief Financial Officer | M Exercise | 2021-08-09 | 2021-08-11 | 26,892 | $3.72 | $100.0K | 53,784 | SEC↗ |
| Biller Scott | Director | A Award deriv | 2021-07-13 | 2021-07-14 | 12,530 | — | $0 | 12,530 | SEC↗ |
| Cole Douglas G. | Director | A Award deriv | 2021-07-13 | 2021-07-14 | 12,530 | — | $0 | 12,530 | SEC↗ |
| GILL SIMBA | Director | A Award deriv | 2021-07-13 | 2021-07-14 | 12,530 | — | $0 | 12,530 | SEC↗ |
| KADOCH CIGALL | Director, 10% Owner | A Award deriv | 2021-07-13 | 2021-07-14 | 12,530 | — | $0 | 12,530 | SEC↗ |
| Koppel Adam | Director | A Award deriv | 2021-07-13 | 2021-07-14 | 12,530 | — | $0 | 12,530 | SEC↗ |
| Mendelsohn Michael | Director | A Award deriv | 2021-07-13 | 2021-07-14 | 12,530 | — | $0 | 12,530 | SEC↗ |
| SMITH IAN F | Director | A Award deriv | 2021-06-23 | 2021-06-24 | 12,530 | — | $0 | 12,530 | SEC↗ |
| SMITH IAN F | Director | A Award deriv | 2021-04-27 | 2021-04-29 | 25,060 | $11.50 | $288.2K | 25,060 | SEC↗ |
| GOTTSCHALK ADRIAN | See Remarks | A Award deriv | 2021-01-28 | 2021-02-01 | 300,000 | — | $0 | 300,000 | SEC↗ |
| Reine Allan | Chief Financial Officer | A Award deriv | 2021-01-28 | 2021-02-01 | 120,000 | — | $0 | 120,000 | SEC↗ |
| Agresta Samuel | Chief Medical Officer | A Award deriv | 2021-01-28 | 2021-02-01 | 100,000 | — | $0 | 100,000 | SEC↗ |
| DECICCO CARL | Chief Scientific Officer | A Award deriv | 2021-01-28 | 2021-02-01 | 100,000 | — | $0 | 100,000 | SEC↗ |
| LaCascia Michael | Chief Legal Officer | A Award deriv | 2020-11-17 | 2020-11-18 | 162,162 | — | $0 | 162,162 | SEC↗ |
| Abu Dhabi Investment Authority | Other | C Conversion deriv | 2020-10-27 | 2020-10-28 | 2,000,001 | — | $0 | 0 | SEC↗ |
| Flagship Ventures Opportunitie | 10% Owner | C Conversion deriv | 2020-10-27 | 2020-10-29 | 2,666,666 | — | $0 | 0 | SEC↗ |
| Flagship Ventures Opportunitie | 10% Owner | C Conversion deriv | 2020-10-27 | 2020-10-29 | 1,336,293 | — | $0 | 0 | SEC↗ |
| Flagship Ventures Opportunitie | 10% Owner | C Conversion deriv | 2020-10-27 | 2020-10-29 | 3,333,333 | — | $0 | 0 | SEC↗ |
| Flagship Ventures Opportunitie | 10% Owner | C Conversion deriv | 2020-10-27 | 2020-10-29 | 8,333,333 | — | $0 | 0 | SEC↗ |
| Flagship Ventures Opportunitie | 10% Owner | C Conversion deriv | 2020-10-27 | 2020-10-29 | 7,500,000 | — | $0 | 0 | SEC↗ |
| GOTTSCHALK ADRIAN | See Remarks | C Conversion deriv | 2020-10-27 | 2020-10-29 | 7,207 | — | $0 | 0 | SEC↗ |
| GOTTSCHALK ADRIAN | See Remarks | C Conversion deriv | 2020-10-27 | 2020-10-29 | 18,018 | — | $0 | 0 | SEC↗ |
| Abu Dhabi Investment Authority | Other | P Buy | 2020-10-27 | 2020-10-28 | 150,000 | $16.00 | $2.40M | 1,231,081 | SEC↗ |
| Abu Dhabi Investment Authority | Other | C Conversion | 2020-10-27 | 2020-10-28 | 1,081,081 | — | $0 | 1,081,081 | SEC↗ |
| Flagship Ventures Opportunitie | 10% Owner | P Buy | 2020-10-27 | 2020-10-29 | 50,000 | $16.00 | $800.0K | 9,330,878 | SEC↗ |
| Flagship Ventures Opportunitie | 10% Owner | C Conversion | 2020-10-27 | 2020-10-29 | 4,504,504 | — | $0 | 8,558,558 | SEC↗ |
| Flagship Ventures Opportunitie | 10% Owner | C Conversion | 2020-10-27 | 2020-10-29 | 4,054,054 | — | $0 | 4,054,054 | SEC↗ |
| Flagship Ventures Opportunitie | 10% Owner | C Conversion | 2020-10-27 | 2020-10-29 | 1,441,441 | — | $0 | 1,441,441 | SEC↗ |
| Flagship Ventures Opportunitie | 10% Owner | P Buy | 2020-10-27 | 2020-10-29 | 50,000 | $16.00 | $800.0K | 1,491,441 | SEC↗ |
| Flagship Ventures Opportunitie | 10% Owner | C Conversion | 2020-10-27 | 2020-10-29 | 722,320 | — | $0 | 9,280,878 | SEC↗ |
| Flagship Ventures Opportunitie | 10% Owner | C Conversion | 2020-10-27 | 2020-10-29 | 1,801,801 | — | $0 | 1,801,801 | SEC↗ |
| Flagship Ventures Opportunitie | 10% Owner | P Buy | 2020-10-27 | 2020-10-29 | 50,000 | $16.00 | $800.0K | 1,851,801 | SEC↗ |
| GOTTSCHALK ADRIAN | See Remarks | C Conversion | 2020-10-27 | 2020-10-29 | 25,225 | — | $0 | 25,225 | SEC↗ |
| DECICCO CARL | Chief Scientific Officer | P Buy | 2020-10-27 | 2020-10-29 | 5,500 | $16.00 | $88.0K | 258,397 | SEC↗ |